anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a health food product to readily keep a healthy state by positively introducing unnecessary cells into physiological apoptoses.  <P>SOLUTION: This health food product comprises garcinone E, mangostinone or 1,7-dihydroxy-2-isoprenyl-3-methoxyxanthone as an active ingredient. Further, the health food product comprises α-mangostin, β-mangostin or γ-mangostin as an active ingredient and ≤100 mg, preferably 1-50 mg of the active ingredient is orally taken per adult daily. The active ingredients are extracted from the pericarp of Garcinia mangostana Linn. Preferably, the health food product is administered dividedly several times daily. In this case, the intake of the active ingredient for one time is preferably 1-5 mg, more preferably 2-4mg and the α-mangostin has the highest effect as the active ingredient.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Disclosed are shear-thinning hydrogel compositions comprising 0.1 to 5 wt. % (such as 0.1 to 2.5 wt. %) of a microgel particle-forming polymer; and 0.5 to 100 mM of a monovalent and/or polyvalent metal ion salt as a cross-linking agent. The microgel particle-forming polymer is dispersed in an aqueous vehicle, and the hydrogel composition has a pH within the range of 3 to 8. The viscosity of the gel composition reduces when the gel is exposed to shear. Also disclosed are methods of making such compositions, and medical uses of such compositions.
A clinic-based intervention to incorporate syphilis testing with routine HIV bloodwork among HIV-positive men who have sex with men (MSM) attending 4 hospital-based HIV clinics in Toronto and Ottawa will be conducted. The objectives are to determine to what degree the intervention: (1) increases the detection rate of untreated syphilis; (2) increases the proportion of men who undergo syphilis testing at least annually (increased screening coverage); (3) reduces the interval between syphilis tests (increased screening frequency); and (4) reaches men at highest risk according to sexual behaviours. The main hypotheses are that the intervention will increase screening coverage to a minimum of 85% of men undergoing syphilis testing annually, increase screening frequency to a median of 3 tests per person per year, and increase the case detection rate by 75% or more.

The design of this study is a cluster-randomized controlled trial with stepped wedge design that will gradually introduce the intervention across clinics. This pragmatic approach incorporates a concurrent comparison group, allows for assessment of time trends, will be well-powered, and will generate more generalizable results due to its inclusion of multiple clinics. The intervention will be operationalized as standing orders for syphilis serology when there is an order for HIV viral load and/or CD4 cell count. Data sources include (1) syphilis tests submitted to the Public Health Ontario Laboratory; (2) a standardized clinical worksheet and medical chart review to validate diagnoses for screen test positives; and (3) data collected from a subset of patients via their participation in the ongoing Ontario HIV Treatment Network (OHTN) Cohort Study. The latter follows adults in HIV care and collects data using chart reviews and annual face-to-face interviews including measures of sexual behaviour.
The oncologic patients are qualified to head and neck tumor resection in general anesthesia. The anesthesia introduction is performed with single dose of midazolam, fentanyl, rocuronium and propofol/etomidate. Sevoflurane is used in anesthesia maintenance. Patients are transported to ICU after operation. Then they are kept for several hours in analgosedation. All used drugs are given by intravenous continuous infusion. Oxycodone is an analgesic component of analgosedation. Midazolam, dexmedetomidine and/or propofol are used as sedatives (2-3 drugs in every patient). Whole blood samples (2.0 ml) are collected during the study to measure drugs concentrations - 3-4 times during infusion, 5, 10, 15, 30, 60 minutes and 2, 4, 6 hours after the infusion cessation. Vital parameters and bispectral index are monitored during analgosedation and 6 hours after the infusion cessation and noted every 15-60 minutes.
Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
The invention discloses a cefquinome sulfate oil suspension. Every 100mL of the suspension contains the following raw and auxiliary materials: 2-15g of cefquinome sulfate, 0.9-1.0g of surfactant, 5.0-5.1g of colloid protective agent, 2.0-8.0g of suspending agent, 0-0.1g of antioxidant and the balance of oil phase. The high-quality cefquinome sulfate oil suspension with the main drug content of 2-15% is obtained by screening the formula. The used auxiliary materials lower the drug sedimentation volume and sedimentation rate. The product has the advantages of low flowability, low sedimentation rate, high sedimentation volume, high needle penetration property and favorable dispersity after centrifugation. In addition, the inspection on the stability under different temperature conditions further proves the high quality of the suspension.
The invention discloses a blood-enriching and qi-tonifying compound traditional chinese lozenge and a preparation technology thereof. The blood-enriching and qi-tonifying compound traditional chinese lozenge mainly comprises bighead atractylodes rhizome, jujube, fleece-flower root, dioscorea fordii prain et burkill, jujube kernel, tuber of dwarf lilyturf, radix codonopsis, matrimony vine, alpinia officinarum hance, common fennel fruit, white peony root, semen litchi, poria cocos, pine kernel, chinese cassia tree, radix astragali, chinese angelica, ligusticum wallichii, red sage root, fructus trichosanthis, and immature bitter orange. The above raw materials are subjected to the traditional preparation process to form the lozenge. The blood-enriching and qi-tonifying compound traditional Chinese lozenge has no toxic or side effect and is scientific in compatibility and good in synergistic effect. Therefore, the blood-enriching and qi-tonifying compound traditional Chinese lozenge has the efficacies of invigorating spleen and benefiting lung, thus being suitable for the symptomatic treatment on various symptoms caused by the deficiency of qi and blood. Meanwhile, the symptoms of dizziness, tinnitus, laminitis, soreness of waist, back pain, insomnia, dreaminess, palpitations, shortness of breath, eupyrexia of hand centre and sole centre, skin dim and reluster are relieved. In addition, the lozenge prepared by the above method is reasonable in formula, simple in preparation process and good in molding effect. The bitter taste of the compound traditional Chinese lozenge is covered up by menthol, so that the compound traditional Chinese lozenge is good in mouthfeel. Therefore, the compound traditional Chinese lozenge is very convenient to take for people.
Negative expectations can increase pain, but can they promote the development of central sensitization? This study used an inert treatment and verbal suggestions to induce expectations of increased high-frequency electrical stimulation (HFS)-induced pain and assessed their effects on pain ratings during HFS and HFS-induced pinprick hypersensitivity. Fifty healthy volunteers were randomly allocated to either a control group (N = 25) or a nocebo group (N = 25). Participants in both groups received a patch containing water on the right forearm. The nocebo group was told that the patch contained capsaicin that sensitized their skin, while the control group was told that the patch contained water that had no effect on skin sensitivity. Before and after patch attachment, single electrical stimuli were delivered to the area of the patch to measure the perceived intensity to these stimuli. After patch removal and after the participant rated expected pain and fear for HFS, HFS was delivered to the same skin site, followed by the assessment of pinprick sensitivity. The nocebo group rated the perceived intensity for the single electrical stimulus after removal of the patch as more intense compared with the control group, indicating that our manipulation worked. Yet, this effect did not transfer to expected pain for HFS, nor did it affect pain intensity ratings during HFS. HFS increased pinprick sensitivity but no group differences were found. Because of the lack of differences in expected pain and pain intensity ratings for HFS between groups, no firm conclusions can be drawn regarding their effect on pinprick hypersensitivity. PERSPECTIVE: This study shows that sham treatment combined with verbal suggestions induces a nocebo effect but does not necessarily change expectations and experience of upcoming pain.
Several studies using HD animal models have shown that HD mice housed in enriched environments or in cages with running wheels that stimulated physical activity demonstrated a delayed onset and/or slowed decline in motor function compared to mice in non-enriched environments (van Dellen et al. 2000, 2008; Spires et al., 2004). Evidence suggests that aerobic exercise may have neuroprotective effects and helps the elderly and individuals with neurodegenerative diseases to maintain better cognitive and motor function than those who are inactive. More specifically, there is strong evidence from animal and human trials in neurological populations (i.e., Parkinson's Disease, spinal cord injury, and stroke) that treadmill training can improve walking and motor function. Immediate effects of a single-session of treadmill walking in the Parkinson's Disease population were improved over-ground gait measures (i.e., gait speed, stride length, double support percent, stride variability) and longer term treadmill training studies demonstrated additional improvements in Unified Parkinson Disease Rating Scale scores, fall risk, and health-related quality of life (Herman et al., 2008). This study builds upon foundational knowledge gained in animals and other neurologic populations to determine the feasibility, safety and possible immediate benefit of treadmill walking in individuals with HD.

The primary purpose of this pilot study is to investigate the the safety, feasibility and utility of a single 20-minute session of treadmill walking to improve gait parameters in ambulatory individuals with DLB and HD. Secondarily we will explore the effects of treadmill walking on mobility, fall risk, and motor coordination. Based on previous studies utilizing a single-session of treadmill training in the PD population, we hypothesize that treadmill walking will improve overground spatiotemporal gait parameters (gait speed, stride length, double support percent, and stride-to-stride variations in gait) in individuals with DLB and HD (Pohl et al., 2003; Frenkel-Toledo et al., 2005; Bello et al., 2008).
Prescribe Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension for the shortest duration that is consistent with individual patient treatment goals [see Warnings and Precautions (5.1)].

Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy [see Warnings and Precautions (5.2)].

Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [see Warnings and Precautions (5.4)]. If a patient requires a refill, reevaluate the cause of the cough and assess the need for continued treatment with Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, the relative incidence of adverse reactions, and the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)].

Do not abruptly discontinue Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension in a physically-dependent patient [see Drug Abuse and Dependence (9.3)]. When a patient who has been taking Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension regularly and may bephysically dependent no longer requires therapy with Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, taper the dose gradually, by25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patientdevelops these signs or symptoms, raise the dose to the previous level and taper more slowly, either byincreasing the interval between decreases, decreasing the amount of change in dose, or both.
The increase in the elderly population brings with it many health problems, especially in older ages. Rates of limitation and disability are increasing in elderly individuals due to chronic diseases. Many of these changes negatively affect their daily living activities. With aging, respiratory muscle strength and respiratory surface area decrease in the cardiopulmonary system. Respiration is negatively affected by the decrease in muscle strength. Postural correctness cannot be easily achieved in elderly individuals due to deterioration in bone, muscle and joint structures. Functional mobility and balance problems are observed with changes in postural control that occur with aging. There are not enough studies in the literature to clarify this issue that evalatues dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. Therefore, the aim of our study is to evaluate dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. Therefore, we aimed to clarify this gap.
Disclosed is a method for recovering peripheral blood containing a population of cells enhanced in human mesenchymal stem cells from an individual by (i) administering to said individual at least one growth factor and, thereafter, (ii) recovering peripheral blood from said individual. The growth factors preferably include G-CSF, GM-CSF and combinations thereof. Any of the known human growth factors or combinations thereof are suitable. Also disclosed is a method for recovering an isolated, culture-expanded population of human mesenchymal stem cells from the mesenchymal stem cell-enriched peripheral blood of an individual. Also disclosed is a method for preserving ex vivo an isolated, culture-expanded population of human mesenchymal stem cells from the mesenchymal stem cell-enriched peripheral blood. Also disclosed is a method for treating an individual with an isolated, culture-expanded population of human mesenchymal stem cells.
PURPOSE:To obtain a pharmaceutical for promoting oral absorption of vitamin E, by blending vitamin E with a polyethyleneglycol fatty acid ester based surfactant. CONSTITUTION:1 pts.wt. vitamin E (e. g., tocopherol or acetic acid tocopherol) is blended with 0.01-10 pts.wt. polyethylene glycol fatty acid ester based surfactant and as necessary oils and fats such as fatty acid or vegetable oil to provide the pharmaceutical having excellent oral absorption. The polyethylene glycol fatty acid ester based surfactant is obtained by esterification of a 12-20C fatty acid with polyethylene glycol. Solubility of vitamin E and absorption from digestive tract are enhanced and bioavailability is improved by the above- mentioned invention.
Iron chelation's mechanism of action (MOA) in Alzheimer's disease (AD) is uncertain. Potential MOA include reversal of aluminum (AL) toxicity, the prevention of a-beta aggregation, β-amyloid disaggregation, and the obstruction of microbacterial and viral parasitism. The latter mechanism involves augmentation of innate immunity, and disruption of microbacterial iron metabolism. Infectious models of AD's pathophysiology have been recently proposed. Iron blocks toll-like receptor (TLR) initiated anti-microbial actions mediated via gamma-interferon (IFN-γ) tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-10 (IL-10). These biomarkers are of interest because they have also been associated with our novel latent dementia phenotype (i.e., "d" for "dementia") in the Texas Alzheimer's Research and Care Consortium (TARCC). "d" is a continuous measure of dementia severity that can be constructed from any cognitive battery that also includes a measure of Instrumental Activities of Daily Living (IADL). Serum biomarkers might "trigger" dementing processes without participating in their later stages. Thus, the investigators have indications as to who might benefit from iron-chelation and when the intervention might be best applied. This knowledge may help them detect an effect of deferiprone on prospective change in "d" and even on MCI conversion in TARCC NHW (Non Hispanic White) subjects.
The invention belongs to technology of traditional Chinese medicine instruments and particularly relates to a medicinal pillow manufactured with thirty two medicinal herbs. The medicinal pillow comprises a pillow case and a pillow interior. Stuffing in the pillow interior is prepared from ginseng, platycodon grandiflorum, cistanche deserticola ma, radix peucedani, asarum sieboldii, radix cynanchi atrati, angelica sinensis, ligusticum wallichii, seedlings of xiongqiong, radix ligustici sinensis, radix angelicae dahuricae, radix aucklandiae, wrinkled gianthyssop herbs, bark of eucommia, biond magnolia flowers, fructus gleditsiae, pericarpium zanthoxyli, capsicum annuum, dried ginger, catenella, platycladi seeds, common coltsfoot flowers, radix aconiti carmichaeli, coix seeds, radix et rhizoma veratri, radix saposhnikoviae, vitex trifolia L, Chinese arborvitae branchlet, aconite, manglietia, alfalfa and latifolia L. typha. The medicinal pillow has the following beneficial effects that a medicinal pillow therapy is not restricted by medical conditions and equipment, and a user only needs to sleep on the pillow. The medicinal pillow is economical and practical, and medicinal materials can be saved to the maximum extent. Although much medicine is used in the medicinal pillow, the medicinal pillow is only used for a few months or up to one year, and daily dosage is small on average. The treatment range is wide, and the curative effect is reliable.
Consumption of 221.24 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
The utility model relates to a composition of a stabilized tablet containing vitamin K, vitamin D and metal salts - calcium and magnesium, which finds application in pharmaceutical practice in the field of human medicine. The stabilized tablet, object of this utility model, has good physical, organoleptic and therapeutic properties, quickly releases the active substance in the body and is stable during storage. This effect is achieved through the double coated components of the vitamin complex, vitamin K and vitamin D, which are embedded in the tablet in quantitative ratios to each other by weight. % : vitamin K and vitamin D from 16 to 24, excipients 76-84. The excipients are: diluents - calcium carbonate, lactose monohydrate, pregelatinized corn starch; glidants - magnesium stearate and magnesium oxide; absorbents - colloidal silicon dioxide; antioxidants - butylated hydroxytoluene and disintegrants - microcrystalline cellulose. The presence of a vitamin complex coated with two layers of hydrophobic material effectively protects the vitamin complex from direct contact with metal ions, penetration of moisture and oxygen from the environment, conditions that provide increased protection of the complex during tableting and storage, as well as under conditions of temperature up to 70 degrees during the tableting.
The present disclosure relates to agents, compositions targeting to von Willebrand factor (VWF). The VWF targeting agents are synthetic polynucleotides, including VWF binding agents and their reversal agents. The VWF binding agents are VWF binding aptamers that bind to and inhibit the VWF activities. The VWF binding agents can be reversed using reversal agents to reverse the inhibitory effect and thereby restore VWF activities. The disclosure further provides methods for regulating the activities of VWF, thereby modulating VWF mediated platelet functionality, such as thrombosis. the present VWF targeting agents may be used for preventing thrombus formation and treating thrombotic disorders.
In clinical trials with diclofenac sodium topical gel, 2 to 3% of subjects had elevations of liver function tests (LFTs) [see Clinical Trials Experience (6.1)]. To minimize the potential risk for an adverse liver-related event in patients treated with diclofenac sodium topical gel, use the lowest effective dose for the shortest duration possible. Exercise caution when prescribing diclofenac sodium topical gel with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, anti-epileptics). 

Physicians should measure transaminases at baseline and periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac.

If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, abdominal pain, diarrhea, dark urine, etc.), diclofenac sodium topical gel should be discontinued immediately. 

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue diclofenac sodium topical gel immediately, and perform a clinical evaluation of the patient.
The paste comprises a vehicle in which is dispersed a dental abrasive which is wholly or partly charcoal. The amt. of charcoal in the compsn. is pref. 5-70%, pref. as a powder of 5-10 micron particle size. It is pref. combined with at least one other abrasive from natural CaCO3, pptd. CaCO3, alpha alumina trihydrate, amorphous silica, kaolins and talc. Besides having a satisfactory abrasive action, the charcoal has an absorbing and purifying effect particularly for colorants such as nicotine stains and for bacteria.
This is a single-arm open-label pilot Phase II study. Following informed consent, eligible subjects will undergo excisional biopsy of a lymphoma-containing lymph node for diagnosis and for generation of the Oncoquest-L vaccine. Patients will receive subcutaneous injections consisting of their autologous tumor-derived Oncoquest-L vaccine starting at approximately 4 to 8 weeks after the biopsy. The first two doses will be given at a 2-week interval and the remaining 3 doses at monthly intervals. Patients will be monitored for response by performing imaging studies at baseline and 1 month after the fifth vaccination (Week 19). Additional imaging studies will be performed every 3 months for the first year and every 6 months during the second year until relapse or disease progression whichever occurs sooner.